Invivyd Inc (NAS:IVVD)

$ 0.51 -0.0204 (-3.85%) Market Cap: 61.00 Mil Enterprise Value: -44.23 Mil PE Ratio: 0 PB Ratio: 0.73 GF Score: 30/100

Q3 2024 Invivyd Inc Earnings Call Transcript
Nov 14, 2024

$0.7905 (-11.18%)

Earnings
Q2 2024 Invivyd Inc Earnings Call Transcript
Aug 14, 2024

$0.98 (-7.55%)

Earnings
Q3 2023 Invivyd Inc Earnings Call Transcript
Nov 09, 2023

$1.4 (-7.89%)

Earnings
Invivyd Inc at Guggenheim Securities Inflammation & Immunology Conference Transcript
Nov 07, 2023
Invivyd Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Q2 2023 Invivyd Inc Earnings Call Transcript
Aug 10, 2023

$1.55 (-0.64%)

Earnings
Invivyd Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Q1 2023 Invivyd Inc Earnings Call Transcript
May 11, 2023

$1.43 (+0.70%)

Earnings
Invivyd Inc at H.C. Wainwright BioConnect Investor Conference Transcript
May 02, 2023
Full Year 2022 Invivyd Inc Earnings Call Transcript
Mar 23, 2023

$1.43 (+0.70%)

Earnings
Q3 2022 Invivyd Inc Earnings Call Transcript
Nov 10, 2022

$3.56 (+7.55%)

Earnings

Invivyd Inc at Jefferies Healthcare Conference Transcript

Jun 09, 2023 / 03:30PM GMT

Release Date Price: $1.3 (-3.70%)

Transcript

Michael Jonathan Yee

Jefferies LLC, Research Division - Equity Analyst

All right. Thank you. Good morning. Thank you for joining us on another great session here for Jefferies Healthcare Conference. Very happy to have the CEO of Invivyd, Dave Hering up here with us. We have a nice introduction of presentation of a few slides, tell us a little bit about the story, and I certainly have lots of questions to ask, and we'll have a nice fireside.

David Hering

Invivyd, Inc. - CEO & Director

All right. Thanks, Michael. It's great to be here. Yes, I think just starting for our legal folks, a whole bunch of forward-looking statements. All is posted on our website as well. And one of the things I think I wanted to start with is I get this question frequently about, okay, we're now into year 3 plus of COVID-19. We've got vaccines, we've got oral antivirals. What really is the unmet need? And what are you trying to solve?

And really there's a multitude of patients that we still see have a huge need related to COVID therapeutics and one that is, in particular

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.